Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Spermine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.93 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.63 |
| ▸ | UBE2N | P61088 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.93 |
| ▸ | CA12 | O43570 | 5/20 | 0.93 |
| ▸ | CA6 | P23280 | 5/20 | 0.93 |
| ▸ | CA7 | P43166 | 5/20 | 0.93 |
| ▸ | CA9 | Q16790 | 5/20 | 0.93 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.93 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.93 |
| ▸ | CA4 | P22748 | 4/20 | 0.93 |
| ▸ | CA5A | P35218 | 4/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.93 |
| ▸ | F13A1 | P00488 | 2/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | THPO | P40225 | 2/20 | 0.93 |
| ▸ | CASP2 | P42575 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spermine SCHEMBL7709508 | 1.00 | UBE2N (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermine SCHEMBL348194 | 1.00 | UBE2N (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermine SCHEMBL15300022 | 1.00 | UBE2N (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermine SCHEMBL1167355 | 1.00 | UBE2N (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermidine SCHEMBL343877 | 0.97 | LMNA (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermidine SCHEMBL573341 | 0.97 | LMNA (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermidine SCHEMBL573651 | 0.97 | LMNA (1.00) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8021183 | 0.97 | UBE2N (0.93) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8405003 | 0.97 | UBE2N (0.93) | UBE2NMAPTPMP22LMNASMN1; SMN2 | |
| Spermine SCHEMBL30354062 | 0.97 | UBE2N (0.93) | UBE2NMAPTPMP22LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003055890-A1 | THIENOPYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055489-A1 | 2,4-DIAMINO-PYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| US-20250000942-A1 | PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATIVE ORGAN FUNCTION | PRINCE BIOTECH, LLC | 2025-01-02 | — | — | US | disclosed |
| CN-118980553-A | Size-based separation of dissociated fixed tissue | 文塔纳医疗系统公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-110520735-B | Size-based separation of dissociated fixed tissue | 文塔纳医疗系统公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240210288-A1 | Representative Diagnostics | VENTANA MED SYST INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11959838-B2 | Representative diagnostics | VENTANA MEDICAL SYSTEMS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230125630-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | UNIV MARYLAND (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4082557-A2 | PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATIVE ORGAN FUNCTION | Bioincept LLC (US) | 2022-11-02 | — | — | EP | disclosed |
| US-11472927-B2 | Polyphosphazenes, methods of making, and uses thereof | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2022-10-18 | — | — | US | disclosed |
| US-6294136-B1 | SYSTEM COMPRISING SINGLE NUCLEIC ACID MOLECULE ELONGATED AND FIXED ALONG ITS LENGTH ONTO SOLID PLANAR SURFACE TO BE INDIVIDUALLY ANALYZABLE AND ACCESSIBLE FOR ENZYMATIC AND/OR HYBRIDIZATION REACTIONS, IMAGING DEVICE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-09-25 | — | — | US | disclosed |
| EP-1058562-A1 | COMPOSITIONS AND METHODS OF TREATING TUMORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6147198-A | NUCLEOTIDE SEQUENCES ELONGATED AND FIXED LENGTHWISE ON A SURFACE; FOR USE AS DIAGNOSTIC TOOLS DURING SEQUENCING AND GENOME ANALYSIS | NEW YORK UNIVERSITY (US) | 2000-11-14 | — | — | US | disclosed |
| WO-1999044645-A1 | COMPOSITIONS AND METHODS OF TREATING TUMORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-09-10 | — | — | WO | disclosed |
| EP-0871640-A1 | METHODS FOR MEASURING PHYSICAL CHARACTERISTICS OF NUCLEIC ACIDS BY MICROSCOPIC IMAGING | NEW YORK UNIVERSITY (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5720928-A | Image processing and analysis of individual nucleic acid molecules | NEW YORK UNIVERSITY (US) | 1998-02-24 | — | — | US | disclosed |
| WO-1997031107-A2 | HUMAN SERUM LECTIN - INDUCED APOPTOSIS AND METHOD FOR DETECTING APOPTOSIS | COLES JOHN G (CA) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997011691-A1 | TREATMENT OF HUMAN PROSTATE CANCER WITH SPERMINE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1997-04-03 | — | — | WO | disclosed |
| WO-1996031522-A1 | METHODS FOR MEASURING PHYSICAL CHARACTERISTICS OF NUCLEIC ACIDS BY MICROSCOPIC IMAGING | NEW YORK UNIVERSITY (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125630-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | PHOSPHO1, PLCG2, PLCG1 | CA2 384/4885ESR1 3224/4885UBE2N 2578/4885 |
| US-11472927-B2 | Polyphosphazenes, methods of making, and uses thereof | PHOSPHO1, PLCG2, PLCG1 | CA2 384/4885ESR1 3224/4885UBE2N 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.